Mixed trend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend down since Sep 11 · below the Ichimoku cloud · RSI 30 · MACD below its signal
| 14.00 | 52-week high | +57.13% |
| 13.41 | Previous month high | +50.51% |
| 10.45 | Previous week high | +17.28% |
| 9.85 | Previous month low | +10.61% |
| 9.45 | Previous week low | +6.06% |
| 9.39 | R3 (classic) | +5.35% |
| 9.24 | R2 (classic) | +3.74% |
| 9.10 | Previous day high | +2.13% |
| 9.08 | R1 (classic) | +1.87% |
| 8.93 | Pivot | +0.26% |
| 8.91 | Price now | |
| 8.79 | Previous day low | −1.35% |
| 8.77 | S1 (classic) | −1.61% |
| 8.62 | S2 (classic) | −3.22% |
| 8.46 | S3 (classic) | −5.09% |
| 4.35 | 52-week low | −51.18% |
None of the 29 investors followed here reported a position in CADL in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CADL trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.4 | -10.1 | -6.7 | 26.1 | 34.3 | 24.1 | -2.8 | 30.6 | -20.1 | -14.7 | +57.7% | ||
| 2025 | -18.5 | 26.9 | -37.0 | -13.1 | 11.0 | -7.2 | 27.4 | -10.2 | -11.9 | 5.5 | -11.3 | 18.4 | −34.9% |
| 2024 | -11.6 | 43.1 | -15.1 | 346.2 | 26.2 | -30.3 | -4.4 | 13.8 | 2.7 | -23.8 | -10.9 | 84.5 | +490.5% |
| 2023 | 43.6 | -30.0 | -25.0 | -4.4 | 17.1 | -16.6 | -14.3 | 13.0 | -24.6 | -2.2 | -0.1 | 63.5 | −17.9% |
| 2022 | -45.1 | -4.0 | 23.5 | -29.7 | 5.3 | -14.1 | -4.3 | 11.9 | -9.5 | -38.2 | -9.8 | 2.3 | −77.1% |
| 2021 | 5.9 | 34.8 | 3.6 | -7.7 | -24.5 | +3.0% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 10, 2026 | Tak Paul PeterChief Executive Officer | Sale at price 10.46 - 11.50 per share. | 280.2K | $3.16M |
| Sep 9, 2026 | Tak Paul PeterChief Executive Officer | Conversion of Exercise of derivative security at price 1.55 per share. | 125K | $193.75K |
| Aug 16, 2026 | Tyagarajan Seshu PChief Technology Officer | Sale at price 12.00 per share. | 7K | $84.00K |
| Jun 28, 2026 | Barone FrancescaOfficer | Sale at price 10.06 per share. | 23.4K | $235.77K |
| Jun 28, 2026 | Tyagarajan Seshu PChief Technology Officer | Sale at price 10.02 per share. | 7K | $70.15K |
| Feb 22, 2026 | Manning Paul B.Director | Purchase at price 5.45 per share. | 550.5K | $3.00M |
| Jul 27, 2025 | Nichols Williams GarrettOfficer | Sale at price 6.98 per share. | 937 | $6.54K |
| Jul 27, 2025 | Nichols Williams GarrettOfficer | Conversion of Exercise of derivative security at price 1.29 per share. | 937 | $1.21K |
| Jun 29, 2025 | Nichols Williams GarrettOfficer | Sale at price 5.04 per share. | 781 | $3.94K |
| Jun 29, 2025 | Nichols Williams GarrettOfficer | Conversion of Exercise of derivative security at price 1.29 per share. | 781 | $1.01K |
| Jun 24, 2025 | Papa Joseph CDirector | Stock Award(Grant) at price 4.67 per share. | 64.2K | $300.00K |
| Jun 24, 2025 | Manning Paul B.Director | Stock Award(Grant) at price 4.67 per share. | 1.07M | $5.00M |
| Jun 24, 2025 | Nabel Gary J.Director | Stock Award(Grant) at price 4.67 per share. | 5.4K | $25.00K |
| Jun 24, 2025 | Martell ChristopherDirector | Stock Award(Grant) at price 4.67 per share. | 111.3K | $520.00K |
| Jun 24, 2025 | Tak Paul PeterChief Executive Officer | Stock Award(Grant) at price 4.67 per share. | 42.8K | $200.00K |
| Jun 24, 2025 | Barone FrancescaOfficer | Stock Award(Grant) at price 4.67 per share. | 4.3K | $20.00K |
| Jun 24, 2025 | Tyagarajan Seshu PChief Technology Officer | Stock Award(Grant) at price 4.67 per share. | 5.4K | $25.00K |
| Jun 24, 2025 | Loggia Nicoletta Ph.D.Director | Stock Award(Grant) at price 4.67 per share. | 2.1K | $10.00K |
| Jun 24, 2025 | Schoch CharlesChief Financial Officer | Stock Award(Grant) at price 4.67 per share. | 5.4K | $25.00K |
| Mar 18, 2025 | Tak Paul PeterChief Executive Officer | Sale at price 8.77 - 9.00 per share. | 26.2K | $229.62K |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Buy / hold / sell counts